Kintor
Kintor
Kintor

About Us

We focus on dermatology and oncology with substantial unmet medical needs,especially androgen receptor-related diseases,

including alopecia, acne, prostate cancer, liver cancer and other conditions that lack effective treatments. Our diverse product pipeline is built on a foundation of internal research and development, supplemented with licensed products. We are committed to developing the best therapeutics to improve human health.

Picture Name

Small-molecule drugs

Kintor Pharma focuses on dermatology and oncology. Our expanded pipeline now includes AR degraders, AR-PROTAC, mTOR inhibitor, Hedgehog inhibitor, and cMyc inhibitor.

Innovative biologics

Kintor Pharma's first biologic drug is an ALK-1 antibody expected to become a "first-in-class" treatment for multiple cancers. 

Combination therapies

To provide the best treatment for prostate and liver cancers and other diseases, Kintor Pharma is creating a diverse pipeline of combination therapies leveraging our innovative drugs.

Our Platforms

Picture Name

R&D Platform

Kintor Pharmaceuticals has established a globally integrated R&D platform that includes a……

Picture Name
Picture Name

Manufacturing base

 Kintor Pharmaceuticals has developed a modern GMP-certified pharmaceutical manufacturing bas……

Picture Name
Picture Name

Business operation

 In anticipation of the commercial launch of our products, Kintor……

Picture Name

News Center

2025-05-08

Official Commencement Of Global Sales Business Of Whitening And Freckle-Removing Functional Cosmetic Raw Material KT-939

Suzhou, 8 May, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the global sales business of its self-developed KT-939, a functional raw material for whitening and freckle-removing cosmetics, has officially commenced. The Company has recently completed its first sales of this raw material. This signifies that the Company has officially tapped into the functional cosmetic raw material industry with an aim to provide high-quality and safe cosmetic raw material for the global cosmetic market.
Picture Name

2025-05-02

Superior Efficacy Of Clinical Observational Study In Kx-826 In Combination With Minoxidil For The Treatment Of Male Adults With Aga In China Over Minoxidil Monotherapy

Suzhou, 2 May, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that a clinical observational study of KX-826 in combination with minoxidil for the treatment of male adults with AGA in China has reached the primary endpoint.
Picture Name

2025-03-20

Long-Term Safety Phase III Clinical Trial Of KX-826 For The Treatment Of AGA Reached Primary Endpoint

Suzhou, 20 March, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term safety phase III clinical trial of its in-house developed and potential first-in-class KX-826 tincture for the treatment of AGA has obtained top-line results. Results indicated that the Long-term Safety Clinical Trial has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent safety and efficacy.
Picture Name
View more
Picture Name

Work at Kintor

We're developing new products to improve human health,and we're looking for people like you to help shape the future at Kintor Pharmaceuticals.We're building a company based on curiosity, talent, and intellectual capital. We provide employees with opportunities for career development and personal growth.lf you're interested  in joining our team, please send your CV to kintor- HR@kintor. com. cn.

Join Us

Kintor